 Successfully completed Phase 1b trial of AVB-500 in Platinum Resistant Ovarian Cancer with encouraging clinical data showing 60 ORR in the subpopulation that has not previously been treated with bevacizumab On-track to discuss the potential pivotal trial of AVB-500 with FDA this year On-track to initiate Phase 1b2 trial of AVB-500 in Clear Cell Renal Cell Carcinoma in 2H 2020 Current cash and cash equivalents expected to fund operations into 2022HOUSTON, Aug. 03, 2020 GLOBE NEWSWIRE -- Aravive, Inc. Nasdaq: ARAV, a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and financial results for the second quarter ended June 30, 2020.Aravive has made significant progress in the second quarter of 2020, highlighted by the successful completion of our Phase 1b trial evaluating AVB-500 in platinum resistant ovarian cancer with encouraging clinical data setting us up to move into what could be a pivotal study with our lead program, said Gail McIntyre, Ph.D., chief executive officer of Aravive. A preliminary discussion with the FDA suggests an adaptive, randomized, controlled trial with biomarker-based stratification and an interim analysis to drop the control arm could potentially be an efficient pathway to approval. We are very encouraged by the Phase 1b trial results and look forward to formally discussing the data and our development plans with the FDA in the coming months. The Aravive team is also looking forward to advancing both the ovarian cancer and renal cancer programs over the next few months. Second Quarter 2020 Financial Results Revenue for the three and six months ended June 30, 2020 were 0 for both periods, compared to 3.1 million and 4.8 million for the same periods in 2019. Revenue for 2019 was derived solely from the Cancer Prevention Research Institute of Texas CPRIT grant.Total operating expenses for the three and six months ended June 30, 2020 were 5.7 million and 16.0 million, respectively, compared to 6.9 million and 14.4 million for the same periods in 2019.Total operating expenses for the three and six months ended June 30, 2020 included non-cash stock-based compensation expense of 0.5 million and 1.2 million, respectively, compared to 0.9 million and 2.0 million for the same periods in 2019. In addition, as previously reported, during the three months ended March 31, 2020, there was a one-time non-cash charge for impairment of the Companys right-of-use asset and leasehold improvements of 2.9 million.For the three and six months ended June 30, 2020, Aravive reported a net loss of 5.0 million and 15.8 million, or 0.32 per share and 1.02 per share, respectively, compared to a net loss of 3.0 million and 7.7 million, or 0.27 per share and 0.69 per share, for the same periods in 2019.Cash Position As of June 30, 2020, cash and cash equivalents was 60.1 million, compared to 65.1 million as of December 31, 2019. The Company expects that its current cash and cash equivalents will be sufficient to fund its operating plans into 2022. Recent Corporate Highlights AVB-500 in Platinum Resistant Ovarian Cancer PROC: On July 23, 2020, the Company announced the successful completion of its Phase 1b trial of AVB-500 in PROC and selection of the recommended Phase 2 dose. o AVB-500 plus paclitaxel showed an overall Investigator-assessed best response rate per RECIST V1.1 of 35 95 CI of 16 to 57 across all dosing cohorts with 2 complete responses CR and 6 partial responses PR. These data compare favorably to the average response rate in platinum-resistant ovarian cancer patients of 10-15.1 oThe Company is encouraged with 60 ORR in the sub population that has not been previously treated with bevacizumab and 71 among those with high plasma sAXLGAS6 ratio, a potential biomarker of response. oAnalysis of all safety data to date showed that AVB-500 has been well-tolerated with no dose-limiting toxicities or unexpected safety signals. oWhile the Phase 1b trial was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mgkg cohort experienced clinical benefit, with 1 CR patient continues to maintain CR for 3 months on AVB-500 alone following discontinuation of paclitaxel, 2 partial responses, and 2 stable disease. oThe safety, pharmacokinetic and clinical activity at the 15 mgkg dose support advancing 15 mgkg AVB-500 into the next, potentially registrational enabling PROC trial. An interim analysis of this study is expected in 2021. AVB-500 in Clear Cell Renal Cell Carcinoma ccRCC: Aravive is on-track to initiate a Phase 1b2 trial of AVB-500 in ccRCC in the second half of 2020. This is an open-label study which is expected to provide safety, pharmacokinetic, and preliminary clinical activity during the upcoming year. This study will also explore the biomarkers that have been identified during the PROC study. Investigator-Sponsored Trials ISTs: The Company expects to provide an update on the ongoing ISTs within the next 12 months assuming COVID-19 and other unforeseen circumstances do not interfere. Strategic Decision to Focus on Oncology Assets and Pipeline Expansion: The Company announced a new strategic focus for AVB-500 in oncology. Following the positive results from the AVB-500 Phase 1 trial in PROC, Aravive plans to focus its resources on advancing the development of AVB-500 in PROC, ccRCC and potentially additional oncology indications. o Recent preclinical data with AVB-500 has highlighted its promise to be combined with various oncology compounds e.g., PARP inhibitors, bevacizumab, immunotherapy as well as cytotoxic agents to support the Companys pipeline expansion in oncology indications. o Specifically, in addition to Aravives focus on PROC, the Company is also considering moving AVB-500 into frontline therapy in Ovarian cancer in combination with PACPlatinumBevacizumab, all of which have biological rationale and supportive data for potential synergyadditive anti-tumor effects. Importantly, the safety profile of AVB-500 suggests there may not be added toxicity to the first line cocktails used in frontline metastatic ovarian cancer. o The Company expects to announce expansion plans during 2021. I am delighted at the achievements that Gail and her team have made with AVB-500 and we strongly support moving the program forward. With a renewed focus on oncology assets, AVB-500 offers a first-and potentially best-in-class opportunity in oncology, said Fred Eshelman, Pharm.D., chairman of the board of directors. On behalf of the Aravive Board, we look forward to continuing to grow our business, add talent to our management team and Board and assess business development opportunities around our pipeline and ex-U.S.About Aravive Aravive, Inc. Nasdaq: ARAV is a clinical-stage oncology company developing transformative treatments designed to halt the progression of life-threatening diseases. Aravives lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway. On July 23, 2020, Aravive announced the successful completion of a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and selection of the recommended Phase 2 dose, 15 mgkg. Analysis of all safety data to date showed that AVB-500 has been generally well-tolerated with no dose-limiting toxicities or unexpected safety signals. While the Phase 1b trial was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mgkg cohort experienced clinical benefit, with 1 complete response CR, 2 partial responses, and 2 stable disease. Across all cohorts, AVB-500 plus paclitaxel data showed an ORR of 35 823 patients, including 2 CRs and a 60 ORR in paclitaxel patients who had not previously been given bevacizumab. For more information, please visit Statements This communication contains forward-looking statements including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended, express or implied, such as advancing both the ovarian cancer and renal cancer programs over the next few months, being on-track to discuss the potentially pivotal study with FDA this year and initiation of Phase 1b2 trial of AVB-500 in clear cell renal cell carcinoma in second half of 2020, moving into what could be a pivotal trial, expanding the pipeline in oncology and announcement of expansion plans in 2021, an adaptive, randomized, controlled trial with biomarker-based stratification and an interim analysis to drop the control arm potentially being an efficient pathway to approval, an interim analysis of the PROC trial in 2021, current cash and cash equivalents expected to fund operations into 2022, ISTs providing information within the next twelve months, moving AVB-500 into frontline therapy in ovarian cancer and the suggestion that AVB-500 may not be added toxicity to the first line cocktails used in frontline metastatic ovarian cancer and continuing to grow the business, add talent to the management and Board and assess business development opportunities around the pipeline and ex-U.S. 